Business ❯Finance ❯Investment Strategies
Mergers and Acquisitions Financial Performance Artificial Intelligence AI Hardware Drug Development Market Regulation Market Conditions Nvidia Investing Market Trends
Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.